Skip to main content
Caplight Logo









Osivax

Osivax

Private
LyonHealthcare & Life Scienceshttps://osivax.com/

Last Round

Grant

Aug 26, 2025

Total Funding Raised

$70.97M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Osivax is a biotechnology company that develops a transformative pipeline of universal vaccines designed to provide protection against viruses that mutate rapidly.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Advanced Materials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

universal vaccineuniversal flu vaccineT-cell vaccineinfectious disease vaccineclinical stage biotechnanoparticle vaccinenext-gen vaccinevaccine developmentoligoDOMconserved protein vaccinepan-sarbecovirus vaccinerespiratory virus vaccinegovernment contractspharmaceutical partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Osivax Comparables

Compare Osivax with similar companies based on industry and business-model similarity.

Osivax comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Centivax, Inc.
87%
hVIVO plc
83%
FluGen, Inc.
81%

Osivax Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 26, 2025
Series BMar 4, 2025
GrantDec 5, 2023
GrantJun 23, 2022
VC RoundJul 8, 2020
Grant
Jul 8, 2020

Key People

Founding team and executive leadership

Delphine Guyon-Gellin

Chief Business Development Officer and Chief Operating Officer

Executive Team

Osivax Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 281% MoM.

  • Aug 26, 2025

    $19.5M grant from Public Health Emergency Medical Countermeasures Enterprise.

Osivax Filings

Explore SEC and related filing metadata, where available.

Osivax filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Osivax's valuation, stock price, and market status.

Is Osivax a public or private company?

Osivax is a private company.

What is the current stock price of Osivax?

Osivax is a private company with no public stock price. No recent secondary market data is available.

How much is Osivax worth (valuation)?

Valuation information for Osivax is not publicly available.

Can I buy Osivax stock?

Osivax shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Osivax's last funding round?

Osivax's most recent funding round was Grant on August 26, 2025.

Who are the main investors in Osivax?

Key investors in Osivax include Noshaq.

Will Osivax IPO soon?

No public IPO plans have been announced for Osivax.

How can I track Osivax secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Osivax's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLyon
Employee Range57
Year Founded2017
Last FundingAug 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?